TY - JOUR
T1 - Cognitive dysfunction in systemic lupus erythematosus
T2 - how do we advance our understanding?
AU - Raghunath, Sudha
AU - Glikmann-Johnston, Yifat
AU - Hanly, John G.
AU - Morand, Eric F.
AU - Stout, Julie C.
AU - Hoi, Alberta
N1 - Funding Information:
EFM reports grants from the National Health and Medical Research Council, Australia, during the conduct of the study; grants and personal fees from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Wolf, GlaxoSmithKline, and EMD Serono; and personal fees from Biogen, AbbVie, Neovacs, Sanofi, UCB, Novartis, and Amgen; all of which were outside the submitted work. JCS is a director of Zindametrix, which provides cognitive assessment advice and assists in the implementation of cognitive testing in commercial and academic clinical trials in Huntington's disease; she also conducts professional consultation in neuropsychology and cognitive testing via Stout Neuropsych. AH reports grants from AstraZeneca and Merck Serono outside the submitted work, sponsorship of the Australian Lupus Registry and Biobank which is chaired by AH is received from Janssen, BMS, and UCB and honorarium from AbbVie. All other authors declare no competing interests.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/4
Y1 - 2022/4
N2 - Despite the high reported prevalence and burden of cognitive dysfunction in systemic lupus erythematosus (SLE), there is poor understanding of its aetiology, clinical assessment, and management. In part, this lack of understanding is due to conceptual disorganisation in the available literature. In this Review, we address key knowledge gaps in the nomenclature, assessment, and interpretation of cognitive dysfunction in SLE. We apply basic principles of neuropsychology and incorporate lessons from other disease states to recommend principles that can help researchers to design studies in SLE. Better understanding of the trajectory of cognitive dysfunction in SLE will help to inform therapeutic trials, including the appropriate selection of outcome measures to capture clinically meaningful responses.
AB - Despite the high reported prevalence and burden of cognitive dysfunction in systemic lupus erythematosus (SLE), there is poor understanding of its aetiology, clinical assessment, and management. In part, this lack of understanding is due to conceptual disorganisation in the available literature. In this Review, we address key knowledge gaps in the nomenclature, assessment, and interpretation of cognitive dysfunction in SLE. We apply basic principles of neuropsychology and incorporate lessons from other disease states to recommend principles that can help researchers to design studies in SLE. Better understanding of the trajectory of cognitive dysfunction in SLE will help to inform therapeutic trials, including the appropriate selection of outcome measures to capture clinically meaningful responses.
UR - http://www.scopus.com/inward/record.url?scp=85123115018&partnerID=8YFLogxK
U2 - 10.1016/S2665-9913(21)00331-3
DO - 10.1016/S2665-9913(21)00331-3
M3 - Review Article
AN - SCOPUS:85123115018
SN - 2665-9913
VL - 4
SP - e293-e302
JO - The Lancet Rheumatology
JF - The Lancet Rheumatology
IS - 4
ER -